OXY

Whitestone REIT Adds Specialty Food Component at Lake Woodlands Crossing and Sugar Park Plaza Centers

Retrieved on: 
Tuesday, November 7, 2023
Woodforest National Bank, WSR, NYSE, Heart, OXY, Total Wine & More, Environment, Market Street, Huntsman Corporation, Whitestone, Spice, Halliburton

The Company added Wild Fork , a modern-day meat and seafood market, at Lake Woodlands Crossing, bringing occupancy at the Total Wine anchored center to 100%.

Key Points: 
  • The Company added Wild Fork , a modern-day meat and seafood market, at Lake Woodlands Crossing, bringing occupancy at the Total Wine anchored center to 100%.
  • In addition, Whitestone added Vishala Foods , specializing in spices and produce used in Indian cuisine, at Sugar Park Plaza.
  • “We’re pleased to add a grocery component at the Lake Woodlands Center as well as a market meeting local demands with Vishala Foods at Sugar Park Plaza,” stated Whitestone’s COO, Christine Mastandrea.
  • Vishala joins a highly synergistic merchandising mix at the 90,000 square foot Sugar Park Plaza, which lies at the entrance to the fast-growing Fort Bend County neighborhoods of Stafford, Missouri City, and Sugar land.

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

Retrieved on: 
Wednesday, October 25, 2023
Inspira Health Network, Patent, Infection, OXY, Risk, Patient, Innovation system, Coma, Pharmaceutical industry

RA'ANANA, Israel, Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira "), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.

Key Points: 
  • RA'ANANA, Israel, Oct. 25, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira "), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.
  • The newly granted patent relates to a novel automated self-priming module designed for the INSPIRA ART500 device.
  • In addition to the United States, the Company has initiated patent applications in Europe and several countries in other regions.
  • Inspira's CEO, Dagi Ben-Noon, commented: "We believe that this patent approval represents a further recognition of our unique solution alongside a major milestone towards the INSPIRATM ART500 system and building a global medical solution.

Inspira™ Terminates ATM Program and Provides an Update

Retrieved on: 
Tuesday, October 24, 2023
The War, Hamas, Woman, ATM, OXY, Cryptocurrency, Nursing, Pharmaceutical industry

RA'ANANA, Israel, Oct. 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.

Key Points: 
  • RA'ANANA, Israel, Oct. 24, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) - ("Inspira Technologies" or "the Company"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, today announces the termination of its at-the-market (ATM) equity offering program originally announced on April 4, 2023, taking effect immediately.
  • Furthermore, Inspira Technologies wishes to assure stakeholders that its operations remain unaffected and uninterrupted by the ongoing war that started on October 7, 2023, involving the State of Israel (the "War") and the terror organization Hamas.
  • The Company's workforce, customers, suppliers, and production facilities are currently insulated from the impact of the War.

Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP

Retrieved on: 
Tuesday, October 10, 2023
The Company, Death, Agreement, OXY, CPB, FDA, CORP, MED, CIO, Good, Marketing, Infection, Ventilation, Patient, Food and Drug Administration, Pharmaceutical industry, Medical device

RA'ANANA, Israel, Oct. 10, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs to minimize the need for mechanical ventilation systems, announced today that it had signed a distribution agreement (the "Agreement") with CIO MED GROUP, CORP., a leading technology and medical devices distributor in Central America.

Key Points: 
  • The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject to the receipt of regulatory approval.
  • The parties will collaborate on the marketing and the deployment of the INSPIRA™ ART device line and disposable kits in Central America.
  • Currently, these patients require ventilation and oxygenation via external mechanical ventilation machinery that often causes multiple complications leading to physical damage, infection, and even death.
  • Joe Hayon, president and co-founder of Inspira Technologies, stated, "In this Agreement, we are expanding our offering of innovative products to eight countries in Central America, led by Mexico."

Energy industry unites and demonstrates commitment to decarbonising at record breaking ADIPEC 2023

Retrieved on: 
Friday, October 6, 2023
Georgia Department of Economic Development, Knowledge, Climate change, Economic development, ADNOC, COP28, Decarbonisation measures in proposed UK electricity market reform, Carbon, Climate change mitigation, OXY, ABU, Methane, CCUS, Aviation, DAC, Holcim, SLB, Renewable energy

Across the exhibition floor, over 2,200 energy companies demonstrated unity, forging paths to decarbonisation through action-oriented partnerships and strategic dialogues.

Key Points: 
  • Across the exhibition floor, over 2,200 energy companies demonstrated unity, forging paths to decarbonisation through action-oriented partnerships and strategic dialogues.
  • ABU DHABI, UAE, Oct. 6, 2023 /PRNewswire/ -- ADIPEC 2023 closed today, with the global energy industry delivering a clear message that it is united in its commitment to decarbonise and to fast-track the energy transition, while continuing to meet global energy needs.
  • Tayba Al Hashemi, Chair of ADIPEC 2023 and CEO of ADNOC Offshore said: "2023 has been a transformational year for ADIPEC.
  • The 2023 edition of ADIPEC reinforced the event's status as the premier platform for the energy industry to come together and do business.

Energy industry unites and demonstrates commitment to decarbonising at record breaking ADIPEC 2023

Retrieved on: 
Friday, October 6, 2023
Georgia Department of Economic Development, Knowledge, Climate change, Economic development, ADNOC, COP28, Decarbonisation measures in proposed UK electricity market reform, Carbon, Climate change mitigation, OXY, ABU, Methane, CCUS, Aviation, DAC, Holcim, SLB, Renewable energy

Across the exhibition floor, over 2,200 energy companies demonstrated unity, forging paths to decarbonisation through action-oriented partnerships and strategic dialogues.

Key Points: 
  • Across the exhibition floor, over 2,200 energy companies demonstrated unity, forging paths to decarbonisation through action-oriented partnerships and strategic dialogues.
  • ABU DHABI, UAE, Oct. 6, 2023 /PRNewswire/ -- ADIPEC 2023 closed today, with the global energy industry delivering a clear message that it is united in its commitment to decarbonise and to fast-track the energy transition, while continuing to meet global energy needs.
  • Tayba Al Hashemi, Chair of ADIPEC 2023 and CEO of ADNOC Offshore said: "2023 has been a transformational year for ADIPEC.
  • The 2023 edition of ADIPEC reinforced the event's status as the premier platform for the energy industry to come together and do business.

Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference

Retrieved on: 
Thursday, September 28, 2023
Face, Food and Drug Administration, ART, CPB, Research, Extracorporeal Life Support Organization, Inspira Health Network, ELSO, Hospital, Patient, OXY, FDA, Health, Conference, Food, Medical device, Pharmaceutical industry

RA'ANANA, Israel, Sept. 28, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.

Key Points: 
  • The ELSO conference brings together healthcare institutions, researchers, and industry partners
    RA'ANANA, Israel, Sept. 28, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.
  • ELSO is dedicated to improving a special type of life support called extracorporeal life support, which involves using external devices to support patients with severe breathing and/or heart problems.
  • Inspira will be introducing its new INSPIRA ART device line, revealing the INSPIRA ART100 device at ELSO, which marks a significant achievement by its team of experts.

Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization

Retrieved on: 
Wednesday, September 13, 2023
Infection, ART, Ventilation, Proton Inspira, Patient, OXY, FDA, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

RA'ANANA, Israel, Sept. 13, 2023 /PRNewswire/ -- Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs, announced it had submitted its INSPIRA ART 100, a cardio-pulmonary bypass device, to the U.S. Food and Drug Administration (FDA) via the 510(k) pathway, with potential clearance expected during the first half of 2024.

Key Points: 
  • The Company's vision is to transform external breathing assistance for over 20 million patients each year that require ventilation and oxygenation via external mechanical ventilation machinery.
  • Legacy systems for breathing assistance are causing multiple complications leading to physical damage, infection and possible death.
  • "We are preparing for global deployments of our INSPIRA ART100 systems once FDA clearance is achieved.
  • Our future systems can save millions of lives and change external respiratory aid for over 20 million people each year.

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Shekel, IPO, Human, Marketing, Risk, Research, Extracorporeal Life Support Organization, ELSO, Patient, Blood, OXY, Artificial intelligence, Unitary state, FDA, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Medical device, Pharmaceutical industry, Cryptocurrency, Security (finance), Proton Inspira

RA'ANANA, Israel, Aug. 10, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the second quarter ended June 30, 2023.
  • "We are extremely pleased with our progress in the second quarter of 2023," said Dagi Ben-Noon, Chief Executive Officer of Inspira.
  • Sales and marketing expenses for the three months ended June 30, 2023 were $233,000, a decrease of approximately $72,000 compared to the second quarter of 2022.
  • General and administrative expenses for the three months ended June 30, 2023, were $1 million, a decrease of $400,000 compared to the second quarter of 2022.

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

Retrieved on: 
Wednesday, August 9, 2023
Oxygen, Blood, OXY, ICU, Carbon, Test management, Medical device

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device.
  • The Usability Study included U.S. healthcare professionals who participated in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.
  • Dagi Ben Noon, Inspira Technologies' Chief Executive Officer, stated: "We are advancing with the INSPIRA ART100.
  • The INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.